AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging

Trends in Endocrinology and Metabolism

Volumn 29, Issue 1, 2018, Pages 8-17

  Cordero, Mario D ^a   Williams, Matthew R ^b   Ryffel, Bernhard ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

aging; AMPK; autophagy; NLRP3 inflammasome

Indexed keywords

CRYOPYRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INFLAMMASOME; PATHOGEN ASSOCIATED MOLECULAR PATTERN; SIRTUIN 1; NLRP3 PROTEIN, HUMAN;

AGING; AUTOPHAGY; CASPASE ACTIVATION AND RECRUITMENT DOMAIN; ENDOPLASMIC RETICULUM STRESS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; UNFOLDED PROTEIN RESPONSE; IMMUNOLOGY; METABOLISM;

AGING; AMP-ACTIVATED PROTEIN KINASES; HUMANS; INFLAMMASOMES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 85035129593     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.10.009     Document Type: Review

References (80)

1. López-Otín, C., et al. The hallmarks of aging. Cell 153 (2013), 1194–1217.
2. Finkel, T., The metabolic regulation of aging. Nat. Med. 21 (2015), 1416–1423.
3. Day, E.A., et al. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 28 (2017), 545–560.
4. Burkewitz, K., et al. AMPK as a pro-longevity target. EXS 107 (2016), 227–256.
5. Salminen, A., Age-related changes in AMPK activation: role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. Ageing Res. Rev. 28 (2016), 15–26.
6. Daskalopoulos, E.P., et al. AMPK in cardiovascular diseases. EXS 107 (2016), 179–201.
7. Domise, M., Vingtdeux, V., AMPK in neurodegenerative diseases. EXS 107 (2016), 153–177.
8. Wang, Z., et al. AMPK and cancer. EXS 107 (2016), 203–226.
9. Bullon, P., et al. AMPK/mitochondria in metabolic diseases. EXS 107 (2016), 129–152.
10. O'Neill, L.A., Hardie, D.G., Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493 (2013), 346–355.
11. Zhou, S., et al. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice. Sci. Rep., 7, 2017, 43245.
12. Petursson, F., et al. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res. Ther., 15, 2013, R77.
13. Bujak, A.L., et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab. 21 (2015), 883–890.
14. Bujak, A.L., et al. Reduced skeletal muscle AMPK and mitochondrial markers do not promote age-induced insulin resistance. J. Appl. Physiol., 117, 2014, 171179.
15. Crane, J.D., et al. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell 14 (2015), 625–634.
16. Ding, Y., et al. Absence of AMPKα2 accelerates cellular senescence via p16 induction in mouse embryonic fibroblasts. Int. J. Biochem. Cell Biol. 71 (2016), 72–80.
17. Turdi, S., et al. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell 9 (2010), 592–606.
18. Slámová, K., et al. Adverse effects of AMP-activated protein kinase α2-subunit deletion and high-fat diet on heart function and ischemic tolerance in aged female mice. Physiol. Res. 65 (2016), 33–42.
19. Lamkanfi, M., Dixit, V.M., Mechanisms and functions of inflammasomes. Cell 157 (2014), 1013–1022.
20. Sadatomi, D., et al. Mitochondrial function is required for extracellular ATP-induced NLRP3 inflammasome activation. J. Biochem. 161 (2017), 503–512.
21. Braga, T.T., et al. Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep., 7, 2017, 39884.
22. Heneka, M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493 (2013), 674–678.
23. Duewell, P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
24. Abderrazak, A., et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 4 (2015), 296–307.
25. Youm, Y.H., et al. The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep. 1 (2012), 56–68.
26. Youm, Y.H., et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18 (2013), 519–532.
27. McBride, M.J., et al. The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 313 (2017), E222–E232.
28. Stout-Delgado, H.W., et al. Age-dependent susceptibility to pulmonary fibrosis is associated with NLRP3 inflammasome activation. Am. J. Respir. Cell Mol. Biol. 55 (2016), 252–263.
29. Spadaro, O., et al. Growth hormone receptor deficiency protects against age-related NLRP3 inflammasome activation and immune senescence. Cell Rep. 14 (2016), 1571–1580.
30. Goldberg, E.L., Dixit, V.D., Drivers of age-related inflammation and strategies for healthspan extension. Immunol. Rev. 265 (2015), 63–74.
31. Bauernfeind, F., et al. Aging-associated TNF production primes inflammasome activation and NLRP3-related metabolic disturbances. J. Immunol. 197 (2016), 2900–2908.
32. Ferrucci, L., et al. The origins of age-related proinflammatory state. Blood 105 (2005), 2294–2299.
33. Wu, X., et al. Gene expression of inflammasome components in peripheral blood mononuclear cells (PBMC) of vascular patients increases with age. Immun. Ageing, 12, 2015, 15.
34. Duewell, P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
35. Saresella, M., et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol. Neurodegener., 11, 2016, 23.
36. De Nardo, D., Latz, E., NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 32 (2011), 373–379.
37. Klionsky, D.J., et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12 (2016), 1–222.
38. Pyo, J.O., et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat. Commun., 4, 2013, 2300.
39. Camuzard, O., et al. Sex-specific autophagy modulation in osteoblastic lineage: a critical function to counteract bone loss in female. Oncotarget 7 (2016), 66416–66428.
40. Shirakabe, A., et al. Aging and autophagy in the heart. Circ. Res. 118 (2016), 1563–1576.
41. Shi, C.S., et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13 (2012), 255–263.
42. Jessop, F., et al. Autophagy deficiency in macrophages enhances NLRP3 inflammasome activity and chronic lung disease following silica exposure. Toxicol. Appl. Pharmacol. 309 (2016), 101–110.
43. Liu, Y., et al. Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells. Oncotarget 8 (2017), 34258–34267.
44. Zhong, Z., et al. NF-κB restricts inflammasome activation via elimination of damaged mitochondria. Cell 164 (2016), 896–910.
45. Ko, J.H., et al. Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome–p38 MAPK–NFκB pathways in autophagy- and p62-dependent manners. Oncotarget 8 (2017), 40817–40831.
46. Yu, S.X., et al. Genipin inhibits NLRP3 and NLRC4 inflammasome activation via autophagy suppression. Sci. Rep., 5, 2015, 17935.
47. Abderrazak, A., et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2. Ki mice fed a high-fat diet. Circulation 131 (2015), 1061–1070.
48. Chang, Y.P., et al. Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J. Cell. Physiol. 230 (2015), 1567–1579.
49. Alcocer-Gómez, E., et al. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in major depressive disorder. Pharmacol. Res. 121 (2017), 114–121.
50. Tian, X., et al. Molecular mechanisms determining lifespan in short- and long-lived species. Trends Endocrinol. Metab. 28 (2017), 722–734.
51. Pallauf, K., et al. Resveratrol and lifespan in model organisms. Curr. Med. Chem. 23 (2016), 4639–4680.
52. Zhao, B., et al. Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival. Genes Dis. 3 (2016), 82–87.
53. Garrido-Maraver, J., et al. Critical role of AMP-activated protein kinase in the balance between mitophagy and mitochondrial biogenesis in MELAS disease. Biochim. Biophys. Acta 1852 (2015), 2535–2553.
54. Shimada, K., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
55. Bullón, P., et al. AMPK phosphorylation modulates pain by activation of NLRP3 inflammasome. Antioxid. Redox Signal. 24 (2016), 157–170.
56. Kim, Y., et al. Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetes. J. Lipid Res. 57 (2016), 66–76.
57. Wu, J., et al. A mitochondrion-targeted antioxidant ameliorates isoflurane-induced cognitive deficits in aging mice. PLoS One, 10, 2015, e0138256.
58. Liu, W.C., et al. Melatonin supplementation, a strategy to prevent neurological diseases through maintaining integrity of blood brain barrier in old people. Front. Aging Neurosci., 9, 2017, 165.
59. Volt, H., et al. Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. J. Pineal Res. 60 (2016), 193–205.
60. Wang, X., et al. Melatonin alleviates lipopolysaccharide-compromised integrity of blood–brain barrier through activating AMP-activated protein kinase in old mice. Aging Cell 16 (2017), 414–421.
61. Martínez, G., et al. Endoplasmic reticulum proteostasis impairment in aging. Aging Cell 16 (2017), 615–623.
62. Menu, P., et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis., 3, 2012, e261.
63. Bae, H.R., et al. β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget 7 (2016), 66444–66454.
64. Li, A., et al. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. Mol. Cell. Endocrinol. 434 (2016), 36–47.
65. Li, J., et al. Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. J. Mol. Cell. Cardiol. 86 (2015), 62–74.
66. Price, N.L., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15 (2012), 675–690.
67. de Kreutzenberg, S.V., et al. Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutr. Metab. Cardiovasc. Dis. 25 (2015), 686–693.
68. Gao, R., et al. Sirt1 restrains lung inflammasome activation in a murine model of sepsis. Am. J. Physiol. Lung Cell. Mol. Physiol. 308 (2015), L847–L853.
69. Li, Y., et al. SIRT1 inhibits inflammatory response partly through regulation of NLRP3 inflammasome in vascular endothelial cells. Mol. Immunol. 77 (2016), 148–156.
70. + deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br. J. Pharmacol. 173 (2016), 2352–2368.
71. Li, Y., et al. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology 222 (2017), 552–561.
72. + and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17 (2016), 679–690.
73. López-Otín, C., et al. Metabolic control of longevity. Cell 166 (2016), 802–821.
74. Pietrocola, F., et al. Metabolic effects of fasting on human and mouse blood in vivo. Autophagy 13 (2017), 567–578.
75. Traba, J., et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J. Clin. Invest. 125 (2015), 4592–4600.
76. Martin-Montalvo, A., et al. Metformin improves healthspan and lifespan in mice. Nat. Commun., 4, 2013, 2192.
77. Eisenberg, T., et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat. Med. 22 (2016), 1428–1438.
78. Coll, R.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21 (2015), 248–255.
79. Youm, Y.H., et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21 (2015), 263–269.
80. Dinh, Q.N., et al. Pressor response to angiotensin II is enhanced in aged mice and associated with inflammation, vasoconstriction and oxidative stress. Aging (Albany NY) 9 (2017), 1595–1606.